Microsoft Excel LibreOffice Calc

Eli Lilly & Co. (LLY)

Long-term (Investment) Activity Analysis

Difficulty: Beginner

  • Annual Data
  • Quarterly Data

    • Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.

    Ratios (Summary)

    Eli Lilly & Co., long-term (investment) activity ratios

    Microsoft Excel LibreOffice Calc
    Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
    Net fixed asset turnover 2.59 2.57 2.48 2.46 2.90
    Total asset turnover 0.51 0.55 0.56 0.53 0.66
    Equity turnover 1.97 1.52 1.37 1.28 1.31

    Based on: 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19), 10-K (filing date: 2014-02-19).

    Ratio Description The company
    Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Eli Lilly & Co.'s net fixed asset turnover improved from 2015 to 2016 and from 2016 to 2017.
    Total asset turnover An activity ratio calculated as total revenue divided by total assets. Eli Lilly & Co.'s total asset turnover deteriorated from 2015 to 2016 and from 2016 to 2017.
    Equity turnover An activity ratio calculated as total revenue divided by shareholders' equity. Eli Lilly & Co.'s equity turnover improved from 2015 to 2016 and from 2016 to 2017.

    Net Fixed Asset Turnover

    Eli Lilly & Co., net fixed asset turnover calculation, comparison to benchmarks

    Microsoft Excel LibreOffice Calc
    Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
    Selected Financial Data (USD $ in thousands)
    Revenue 22,871,300  21,222,100  19,958,700  19,615,600  23,113,100 
    Property and equipment, net 8,826,500  8,252,600  8,053,500  7,963,900  7,975,500 
    Ratio
    Net fixed asset turnover1 2.59 2.57 2.48 2.46 2.90
    Benchmarks
    Net Fixed Asset Turnover, Competitors
    Abbott Laboratories 3.60 3.66 3.56 3.41 3.70
    AbbVie Inc. 10.07 9.85 8.91 8.03 8.18
    Allergan PLC 8.93 9.04 9.58 8.19 5.37
    Amgen Inc. 4.37 4.41 4.27 3.70 3.40
    Biogen Inc. 3.86 4.58 4.92 5.50 3.96
    Bristol-Myers Squibb Co. 4.15 3.90 3.75 3.59 3.58
    Celgene Corp. 12.12 12.03 11.25 11.77 10.72
    Gilead Sciences Inc. 7.79 10.45 14.13 14.62 9.26
    Johnson & Johnson 4.50 4.52 4.41 4.61 4.27
    Merck & Co. Inc. 3.23 3.31 3.16 3.22 2.94
    Pfizer Inc. 3.79 3.97 3.55 4.22 4.16
    Regeneron Pharmaceuticals Inc. 2.49 2.33 2.57 2.89 3.99
    Net Fixed Asset Turnover, Sector
    Pharmaceuticals & Biotechnology 4.31 4.44 4.33 4.33 3.96
    Net Fixed Asset Turnover, Industry
    Health Care 7.11 7.33 7.00 6.93 6.50

    Based on: 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19), 10-K (filing date: 2014-02-19).

    2017 Calculations

    1 Net fixed asset turnover = Revenue ÷ Property and equipment, net
    = 22,871,300 ÷ 8,826,500 = 2.59

    Ratio Description The company
    Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Eli Lilly & Co.'s net fixed asset turnover improved from 2015 to 2016 and from 2016 to 2017.

    Total Asset Turnover

    Eli Lilly & Co., total asset turnover calculation, comparison to benchmarks

    Microsoft Excel LibreOffice Calc
    Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
    Selected Financial Data (USD $ in thousands)
    Revenue 22,871,300  21,222,100  19,958,700  19,615,600  23,113,100 
    Total assets 44,981,000  38,805,900  35,568,900  37,178,200  35,248,700 
    Ratio
    Total asset turnover1 0.51 0.55 0.56 0.53 0.66
    Benchmarks
    Total Asset Turnover, Competitors
    Abbott Laboratories 0.36 0.40 0.49 0.49 0.51
    AbbVie Inc. 0.40 0.39 0.43 0.72 0.64
    Allergan PLC 0.13 0.11 0.11 0.25 0.38
    Amgen Inc. 0.27 0.28 0.29 0.28 0.28
    Biogen Inc. 0.52 0.50 0.55 0.68 0.58
    Bristol-Myers Squibb Co. 0.62 0.58 0.52 0.47 0.42
    Celgene Corp. 0.43 0.40 0.34 0.44 0.48
    Gilead Sciences Inc. 0.37 0.53 0.62 0.71 0.48
    Johnson & Johnson 0.49 0.51 0.53 0.57 0.54
    Merck & Co. Inc. 0.46 0.42 0.39 0.43 0.42
    Pfizer Inc. 0.31 0.31 0.29 0.29 0.30
    Regeneron Pharmaceuticals Inc. 0.67 0.70 0.73 0.73 0.71
    Total Asset Turnover, Sector
    Pharmaceuticals & Biotechnology 0.37 0.38 0.38 0.44 0.43
    Total Asset Turnover, Industry
    Health Care 0.54 0.55 0.53 0.61 0.62

    Based on: 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19), 10-K (filing date: 2014-02-19).

    2017 Calculations

    1 Total asset turnover = Revenue ÷ Total assets
    = 22,871,300 ÷ 44,981,000 = 0.51

    Ratio Description The company
    Total asset turnover An activity ratio calculated as total revenue divided by total assets. Eli Lilly & Co.'s total asset turnover deteriorated from 2015 to 2016 and from 2016 to 2017.

    Equity Turnover

    Eli Lilly & Co., equity turnover calculation, comparison to benchmarks

    Microsoft Excel LibreOffice Calc
    Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
    Selected Financial Data (USD $ in thousands)
    Revenue 22,871,300  21,222,100  19,958,700  19,615,600  23,113,100 
    Total Eli Lilly and Company shareholders' equity 11,592,200  14,007,700  14,571,300  15,373,200  17,631,400 
    Ratio
    Equity turnover1 1.97 1.52 1.37 1.28 1.31
    Benchmarks
    Equity Turnover, Competitors
    Abbott Laboratories 0.89 1.02 0.96 0.94 0.87
    AbbVie Inc. 5.54 5.53 5.79 11.46 4.18
    Allergan PLC 0.22 0.19 0.20 0.46 0.91
    Amgen Inc. 0.86 0.73 0.75 0.75 0.82
    Biogen Inc. 0.97 0.94 1.15 0.90 0.80
    Bristol-Myers Squibb Co. 1.77 1.20 1.16 1.07 1.08
    Celgene Corp. 1.87 1.69 1.55 1.16 1.14
    Gilead Sciences Inc. 1.26 1.59 1.73 1.59 0.95
    Johnson & Johnson 1.27 1.02 0.98 1.07 0.96
    Merck & Co. Inc. 1.17 0.99 0.88 0.87 0.88
    Pfizer Inc. 0.74 0.89 0.75 0.70 0.68
    Regeneron Pharmaceuticals Inc. 0.96 1.09 1.12 1.11 1.08
    Equity Turnover, Sector
    Pharmaceuticals & Biotechnology 0.98 0.93 0.88 0.96 0.93
    Equity Turnover, Industry
    Health Care 1.39 1.35 1.24 1.37 1.34

    Based on: 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19), 10-K (filing date: 2014-02-19).

    2017 Calculations

    1 Equity turnover = Revenue ÷ Total Eli Lilly and Company shareholders' equity
    = 22,871,300 ÷ 11,592,200 = 1.97

    Ratio Description The company
    Equity turnover An activity ratio calculated as total revenue divided by shareholders' equity. Eli Lilly & Co.'s equity turnover improved from 2015 to 2016 and from 2016 to 2017.